AKR1C3 and posterior cortical atrophy: Indomethacin, a nonsteroidal anti-inflammatory drug, acts as an inhibitor of AKR1C3 enzymatic activity and, when elevated, is linked to enhanced PCa progression, aggressiveness, and resistance to antiandrogens and radiation therapy [107], and it has been established that that may restore enzalutamide and abiraterone sensitivity in resistant PCa cells by targeting intracrine androgens [108,109].